The new consortium is aiming to make comprehensive genomic profiling accessible to advanced cancer patients in the US, to help inform their treatment decisions.
The study, supported by TargetCancer, Foundation Medicine, and Bayer, aims to match 400 patients with rare cancers to personalized treatments based on NGS.
The collaborators said they're creating a solution for pharmaceutical clients that will encompass everything from patient recruitment to regulatory approvals.
By allowing rare cancer patients to receive genomic profiling and treatments locally, the study investigators are hoping to expand access to molecularly informed care throughout the US.
The study of cancer immunity biomarkers revealed complex immune profiles for most tumors, suggesting the need for customized combinations of immunotherapies.
